Brought to you by 
Janssen Biotech gets rights to Pharmacyclics' PCI32765
05 Oct 2021
Executive Summary
Johnson & Johnson’s Janssen Biotech Inc. (a division of Janssen Pharmaceutical Cos.) has licensed worldwide development and marketing rights to Pharmacyclics Inc.’s (cancer and immune-mediated disease therapeutics) PCI32765, a first-in-class Bruton’s tyrosine kinase inhibitor in Phase II for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen Biotech gets rights to Pharmacyclics' PCI32765
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice